7.04

0.56% -0.04

After Hours: 7.01 -0.03 -0.43%

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is currently priced at $7.04, with a 24-hour trading volume of 1.16M. It has seen a -0.56% decreased in the last 24 hours and a -1.40% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.95 pivot point. If it approaches the $7.29 resistance level, significant changes may occur.

Previous Close:

$7.08

Open:

$8.71

24h Volume:

1.16M

Market Cap:

$931.64M

Revenue:

$25.55M

Net Income/Loss:

$-341.97M

P/E Ratio:

-2.6171

EPS:

-2.69

Net Cash Flow:

$-304.44M

1W Performance:

+10.52%

1M Performance:

-1.40%

6M Performance:

-6.38%

1Y Performance:

-37.20%

1D Range:

$6.79

$8.71

52W Range:

$5.70

$13.32

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

617-370-8837

Address

215 First Street, 3rd Floor, Cambridge

Employee

122

Twitter

Next Earnings Date

2024-05-14

Latest SEC Filings

RLAY's Discussions on Twitter

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

GlobeNewswire Inc.

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

GlobeNewswire Inc.

Relay Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire Inc.

Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?

Zacks Investment Research

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire Inc.

Relay Therapeutics Inc Stock (RLAY) Financials Data

Relay Therapeutics Inc (RLAY) Revenue 2024

RLAY reported a revenue (TTM) of $25.55 million for the quarter ending December 31, 2023, a +1,750% rise year-over-year.

Relay Therapeutics Inc (RLAY) Net Income 2024

RLAY net income (TTM) was -$341.97 million for the quarter ending December 31, 2023, a -17.72% decrease year-over-year.

Relay Therapeutics Inc (RLAY) Cash Flow 2024

RLAY recorded a free cash flow (TTM) of -$304.44 million for the quarter ending December 31, 2023, a -27.62% decrease year-over-year.

Relay Therapeutics Inc (RLAY) Earnings per Share 2024

RLAY earnings per share (TTM) was -$2.80 for the quarter ending December 31, 2023, a -7.69% decline year-over-year.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.